Regenerative medicine is the future, and it comes as no surprise that the biotech space is all over it. Who will be the leading biotech companies utilizing regenerative medicine in the future? That’s the million-dollar question. One emerging company could have explosive growth potential ahead in this rising arena. The Company is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. These allografts are not just any allografts.They are best-in-class perinatal tissue allografts. The company is focused on the diabetic wound care market and the advanced wound care market: two multi-billion-dollar markets that could equate to explosive revenues all while helping patients.
This company recently hit a huge milestone, receiving Investigational Review Board (IRB) approval for a clinical study that aims to investigate the utilization and effects of the company's Vendaje wound care products in Diabetic Foot Ulcers (DFU). DFUs are a significant risk for people with diabetes. Between 14 and 24 percent of people who develop DFU will require an amputation. As BioStem works to achieve its mission of delivering cutting-edge wound care management products, it is strategically addressing a significant market opportunity, adding long-term value for shareholders.
Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO's, CFO's, COO's and other insiders.
This message is a paid advertisement sent on behalf of Huge Alerts, a third-party advertiser of InsiderTrades.com and MarketBeat.
This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency and Huge Alerts. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $12,600. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Sideways Frequency or Huge Alerts. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts' website for additional information about the relationship between Huge Alerts and BioStem Technologies Inc. (OTC: BSEM).
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com or leave us a voicemail at (844) 978-6257.
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
Post a Comment
Post a Comment